Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
All News
Headline News
Press Releases
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
From Natera, Inc.
Via Business Wire
Tickers NTRA
AM Best to Host Annual MENA Insurance Market Briefing in Dubai
From AM Best
Via Business Wire
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
From Genentech
Via Business Wire
Tickers RHHBY
Lone Star Announces Sale of Xella to Holcim
From Lone Star Funds
Via Business Wire
Bass Pro Shops Ranked Highest in 2025 Boat Industry Study Measuring Response to Sales Customer Calls
From Pied Piper Management Company, LLC
Via Business Wire
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products
From Biedermann Motech
Via Business Wire
AM Best to Participate at 2025 Shanghai International Reinsurance Conference
From AM Best
Via Business Wire
AM Best to Host Market Briefing at 2025 Singapore International Reinsurance Conference
From AM Best
Via Business Wire
The Republic of Korea Selects L3Harris for Airborne Early Warning and Control Aircraft Program
From L3Harris Technologies
Via Business Wire
Tickers LHX
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
From Arcus Biosciences
Via Business Wire
Tickers RCUS
F5, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – FFIV
From The DJS Law Group
Via Business Wire
Tickers FFIV
Freshpet, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – FRPT
From The DJS Law Group
Via Business Wire
Tickers FRPT
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
From Incyte
Via Business Wire
Tickers INCY
FFIV Investors Have Opportunity to Join F5, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Tickers FFIV
FRPT Investors Have Opportunity to Join Freshpet, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Tickers FRPT
American Airlines and Citi Launch the Citi / AAdvantage Globe Mastercard
From Citi
Via Business Wire
Tickers C
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
From Summit Therapeutics
Via Business Wire
Tickers SMMT
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
From Daiichi Sankyo
Via Business Wire
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
From Daiichi Sankyo
Via Business Wire
Tickers MRK
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
From AstraZeneca
Via Business Wire
Tickers AZN
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
From Faeth Therapeutics
Via Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
From Corcept Therapeutics Incorporated
Via Business Wire
Tickers CORT
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
From Verastem Oncology
Via Business Wire
Tickers VSTM
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
From Tubulis
Via Business Wire
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
From Daiichi Sankyo
Via Business Wire
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
From Delcath Systems, Inc.
Via Business Wire
Tickers DCTH
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.